Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Adipose-Derived Mesenchymal Stem Cell Clusters in Critical Limb Ischemia
NCT04661644Phase 2Completed
- Sponsor
- S.Biomedics
- Start
- Nov 2020
- Primary completion
- Apr 2024
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of FECS-Ad in critical limb ischemia (CLI), sponsored by S.Biomedics. Started Nov 2020; status: completed.
02
Drugs
FECS-Ad
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT04661644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04661644.